A retrospective review of initial bisphosphonate infusion in an inpatient vs. outpatient setting for bisphosphonate naïve patients
-
Rose M. Kreikemeier
Abstract
Background:
The purpose of this study was to evaluate the safety and convenience of initial bisphosphonate infusion therapy in inpatient and outpatient settings for patients with low bone mineral density.
Methods:
All data were collected from retrospective chart reviews of heterogeneous groups of patients. Abnormal findings prior to the infusion and side effects during the infusion were documented. Patients were contacted following the infusion to discuss post-infusion adverse events.
Results:
The majority of both outpatients (80%, n=44) and inpatients (50%, n=27) did not experience any adverse events related to the infusion. Some patients reported minor adverse events that were expected. Only one of the inpatients had a severe adverse event (SAE) after the infusion.
Conclusions:
For patients at low risk for severe reactions to treatment, the infusion center appears to be a safe and possibly more convenient treatment setting for both the patient and the hospital, although more expensive for the patient at our institution.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta (Review). Cochrane Database Syst Rev 2016;10:CD005088.10.1002/14651858.CD005088.pub4Suche in Google Scholar PubMed PubMed Central
2. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846–50.10.1210/jcem.85.5.6584Suche in Google Scholar PubMed
3. Sees JP, Sitoula P, Dabney K, Holmes L, Rogers KJ, et al. Pamidronate treatment to prevent reoccurring fractures in children with cerebral palsy. J Pediatr Orthop 2016;36: 193–7.10.1097/BPO.0000000000000421Suche in Google Scholar PubMed
4. Iwasaki T, Nonoda Y, Ishii M. Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis. Curr Med Res Opin 2012;28:737–47.10.1185/03007995.2011.645562Suche in Google Scholar PubMed
5. DiMeglio LA. Bisphosphonate therapy for fibrous dysplasia. Pediatr Endocrinol Rev 2007;(Suppl 4):440–5.Suche in Google Scholar PubMed
6. Ooi HL, Briody J, Biggin A, Cowell CT, Munns CF. Intravenous zoledronic acid given every 6 months in childhood osteoporosis. Horm Res Paediatr 2013;80:179–84.10.1159/000354303Suche in Google Scholar PubMed
7. Clark EM, Ness AR, Bishop NJ, Tobias JH. Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res 2006;21:1489–95.10.1359/jbmr.060601Suche in Google Scholar PubMed PubMed Central
8. Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, et al. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Dev Med Child Neurol 2006;48:709–12.10.1017/S0012162206001526Suche in Google Scholar PubMed
9. Henderson RC, Lark RK, Gurka MJ, Worley G, Fung EB, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics 2002;110:e5.10.1542/peds.110.1.e5Suche in Google Scholar PubMed
10. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002;86:356–64.10.1136/adc.86.5.356Suche in Google Scholar PubMed PubMed Central
11. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947–52.10.1056/NEJM199810013391402Suche in Google Scholar PubMed
12. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846–50.10.1210/jcem.85.5.6584Suche in Google Scholar PubMed
13. Baroncelli GI, Bertelloni S. The use of bisphosphonates in pediatrics. Horm Res Paediatr 2014;82:290–302.10.1159/000365889Suche in Google Scholar PubMed
14. Andiran N, Alikasifoglu A, Gonc N, Ozon A, Kandemir N, et al. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation. J Pediatr Endocrinol Metab 2008;21:63–72.10.1515/JPEM.2008.21.1.63Suche in Google Scholar PubMed
15. Levy MC, Kronenberger WG, Carter BD. Brief report: illness factors and child behavior before and during pediatric hospitalization. J Pediatr Psychol 2008;33:905–9.10.1093/jpepsy/jsn039Suche in Google Scholar PubMed PubMed Central
16. Thomas IH, DiMeglio LA. Advances in the classification and treatment of osteogenesis imperfecta. Curr Osteoporos Rep 2016;14:1–9.10.1007/s11914-016-0299-ySuche in Google Scholar PubMed
17. Gomes GL, Nóbrega MM. Anxiety in children following hospitalization: a proposal for a nursing diagnosis. Rev Lat Am Enfermagem 2015;23:963–70.10.1590/0104-1169.0372.2637Suche in Google Scholar PubMed PubMed Central
18. Olson JA. Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report. J Pediatr Rehabil Med 2014;7:155–8.10.3233/PRM-140284Suche in Google Scholar PubMed
19. Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004;35:231–4.10.1016/j.bone.2004.03.008Suche in Google Scholar PubMed
20. Peterson JD, Bedrossian EH. Bisphosphonate-associated orbital inflammation – a case report and review. Orbit 2012;31:119–23.10.3109/01676830.2011.648818Suche in Google Scholar PubMed
21. Chilbule SK, Madhuri V. Complications of pamidronate therapy in paediatric osteoporosis. J Child Orthop 2012;6:37–43.10.1007/s11832-012-0383-5Suche in Google Scholar PubMed PubMed Central
©2017 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Review
- Individualised growth response optimisation (iGRO) tool: an accessible and easy-to-use growth prediction system to enable treatment optimisation for children treated with growth hormone
- Original Articles
- Relation of insulin resistance to neurocognitive function and electroencephalography in obese children
- Body weight misperception and health-related factors among Iranian children and adolescents: the CASPIAN-V study
- Do sufficient vitamin D levels at the end of summer in children and adolescents provide an assurance of vitamin D sufficiency at the end of winter? A cohort study
- Type 3 renal tubular acidosis associated with growth hormone deficiency
- Serum α-klotho levels are not informative for the evaluation of growth hormone secretion in short children
- Evaluation of neurodevelopment of children with congenital hypothyroidism by the Denver Developmental Screening Test
- Pediatric differentiated thyroid carcinoma: trends in practice and outcomes over 40 years at a single tertiary care institution
- Physical activity and bone mineral density at the femoral neck subregions in adolescents with Down syndrome
- A pilot study on the utility of reduced urine collection frequency protocols for the assessment of reproductive hormones in adolescent girls
- MODY in Ukraine: genes, clinical phenotypes and treatment
- A retrospective review of initial bisphosphonate infusion in an inpatient vs. outpatient setting for bisphosphonate naïve patients
- Molecular genetic and clinical delineation of 22 patients with congenital hypogonadotropic hypogonadism
- Letter to the Editor
- Rare cases of galactose metabolic disorders: identification of more than two mutations per patient
- Case Reports
- When one disease is not enough: succinyl-CoA: 3-oxoacid coenzyme A transferase (SCOT) deficiency due to a novel mutation in OXCT1 in an infant with known phenylketonuria
- Pseudohypoparathyroidism type 1B associated with assisted reproductive technology
- Long QT syndrome diagnosed in two sisters with propionic acidemia: a case report
- Delayed diagnosis of proopiomelanocortin (POMC) deficiency with type 1 diabetes in a 9-year-old girl and her infant sibling
Artikel in diesem Heft
- Frontmatter
- Review
- Individualised growth response optimisation (iGRO) tool: an accessible and easy-to-use growth prediction system to enable treatment optimisation for children treated with growth hormone
- Original Articles
- Relation of insulin resistance to neurocognitive function and electroencephalography in obese children
- Body weight misperception and health-related factors among Iranian children and adolescents: the CASPIAN-V study
- Do sufficient vitamin D levels at the end of summer in children and adolescents provide an assurance of vitamin D sufficiency at the end of winter? A cohort study
- Type 3 renal tubular acidosis associated with growth hormone deficiency
- Serum α-klotho levels are not informative for the evaluation of growth hormone secretion in short children
- Evaluation of neurodevelopment of children with congenital hypothyroidism by the Denver Developmental Screening Test
- Pediatric differentiated thyroid carcinoma: trends in practice and outcomes over 40 years at a single tertiary care institution
- Physical activity and bone mineral density at the femoral neck subregions in adolescents with Down syndrome
- A pilot study on the utility of reduced urine collection frequency protocols for the assessment of reproductive hormones in adolescent girls
- MODY in Ukraine: genes, clinical phenotypes and treatment
- A retrospective review of initial bisphosphonate infusion in an inpatient vs. outpatient setting for bisphosphonate naïve patients
- Molecular genetic and clinical delineation of 22 patients with congenital hypogonadotropic hypogonadism
- Letter to the Editor
- Rare cases of galactose metabolic disorders: identification of more than two mutations per patient
- Case Reports
- When one disease is not enough: succinyl-CoA: 3-oxoacid coenzyme A transferase (SCOT) deficiency due to a novel mutation in OXCT1 in an infant with known phenylketonuria
- Pseudohypoparathyroidism type 1B associated with assisted reproductive technology
- Long QT syndrome diagnosed in two sisters with propionic acidemia: a case report
- Delayed diagnosis of proopiomelanocortin (POMC) deficiency with type 1 diabetes in a 9-year-old girl and her infant sibling
